ALT-400

About Altimmune

Altimmune's mission is to develop transformative peptide-based medicines for obesity, liver diseases, and other metabolic disorders. Its strategic pivot from vaccines to metabolic therapeutics is anchored by compelling Phase 2 data for pemvidutide, which showed significant weight loss and resolution of metabolic dysfunction-associated steatohepatitis (MASH). The company's strategy focuses on advancing pemvidutide into late-stage development while leveraging its peptide engineering platform to build a pipeline of targeted multi-agonists.

Therapeutic Areas

Other Undisclosed Metabolic Indication Drugs